Literature DB >> 20472931

Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis.

Isabel Castrejón1, Ana M Ortiz, Esther Toledano, Santos Castañeda, Alberto García-Vadillo, Esther Patiño, Isidoro González-Alvaro.   

Abstract

OBJECTIVE: To estimate the cutoff points for the 28-joint Disease Activity Score (DAS28) calculated using C-reactive protein (CRP) measurements from patients with early arthritis.
METHODS: We analyzed data from 568 visits of 207 patients enrolled in our prospective longitudinal register of early arthritis. Six rheumatologists evaluated the degree of disease activity at each visit on the basis of the available clinical data, and the final degree of disease activity was established by consensus. DAS28 values were calculated for each visit using CRP or erythrocyte sedimentation rate (ESR). Through a ROC analysis, cutoff points for both indices, as well as for minimal disease activity (MDA), were selected on the basis of the best tradeoff values between sensitivity and specificity.
RESULTS: The cutoff values to classify disease activity with the DAS28-CRP were 2.3, 3.8, and 4.9, considering remission at < 2.3, low disease activity 2.3-3.8, moderate disease activity 3.8-4.9, and high disease activity > 4.9. The cutoff value for MDA when calculated with CRP was 2.6. The area under the ROC curves was always greater for DAS28-CRP than for DAS28-ESR, reaching statistical significance for low/moderate activity and for the MDA.
CONCLUSION: Our study confirms that the cutoff points for DAS28-CRP are lower than those described for DAS28-ESR, suggesting that DAS28-CRP may be more accurate to assess disease activity in our population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472931     DOI: 10.3899/jrheum.091333

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.

Authors:  Maria Sole Chimenti; Paola Triggianese; Paola Conigliaro; Marco Tonelli; Gianfranco Gigliucci; Lucia Novelli; Miriam Teoli; Roberto Perricone
Journal:  Clin Rheumatol       Date:  2017-07-31       Impact factor: 2.980

2.  Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.

Authors:  Ashutosh Tamhane; David T Redden; Gerald McGwin; Elizabeth E Brown; Andrew O Westfall; Richard J Reynolds; Laura B Hughes; Doyt L Conn; Leigh F Callahan; Beth L Jonas; Edwin A Smith; Richard D Brasington; Larry W Moreland; S Louis Bridges
Journal:  J Rheumatol       Date:  2013-08-15       Impact factor: 4.666

3.  Serum adenosine deaminase may predict disease activity in rheumatoid arthritis.

Authors:  Batool Zamani; Raika Jamali; Arsia Jamali
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

4.  Health-related quality of life and disease activity in rheumatoid arthritis.

Authors:  Gholam Hossein Alishiri; Noushin Bayat; Ahmad Salimzadeh; Amirhossein Salari; Seyed Morteza Hosseini; Shadi Rahimzadeh; Shervin Assari
Journal:  J Res Med Sci       Date:  2011-07       Impact factor: 1.852

5.  Sustained rheumatoid arthritis remission is uncommon in clinical practice.

Authors:  Femke H M Prince; Vivian P Bykerk; Nancy A Shadick; Bing Lu; Jing Cui; Michelle Frits; Christine K Iannaccone; Michael E Weinblatt; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2012-03-19       Impact factor: 5.156

6.  Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Franco Laghi-Pasini
Journal:  Lupus Sci Med       Date:  2016-12-08

7.  DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable.

Authors:  Roy M Fleischmann; Désirée van der Heijde; Philip V Gardiner; Annette Szumski; Lisa Marshall; Eustratios Bananis
Journal:  RMD Open       Date:  2017-01-30

8.  Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Arthur Kavanaugh; Iain B McInnes; Gerald G Krueger; Dafna Gladman; Anna Beutler; Tim Gathany; Michael Mack; Neeta Tandon; Chenglong Han; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

9.  Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis.

Authors:  Isidoro González-Álvaro; Isabel Castrejón; Ana M Ortiz; Esther Toledano; Santos Castañeda; Alberto García-Vadillo; Loreto Carmona
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

10.  Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.

Authors:  M Schoels; F Alasti; J S Smolen; D Aletaha
Journal:  Arthritis Res Ther       Date:  2017-07-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.